▶ 調査レポート

世界の自己免疫治療市場2022年-2027年:成長・動向・新型コロナの影響・市場予測

• 英文タイトル:Autoimmune Treatment Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

Mordor Intelligenceが調査・発行した産業分析レポートです。世界の自己免疫治療市場2022年-2027年:成長・動向・新型コロナの影響・市場予測 / Autoimmune Treatment Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027) / MRC2203A840資料のイメージです。• レポートコード:MRC2203A840
• 出版社/出版日:Mordor Intelligence / 2022年1月
• レポート形態:英文、PDF、114ページ
• 納品方法:Eメール(受注後2-3営業日)
• 産業分類:医療
• 販売価格(消費税別)
  Single User¥703,000 (USD4,750)▷ お問い合わせ
  Site Licence¥962,000 (USD6,500)▷ お問い合わせ
  Corporate License¥1,295,000 (USD8,750)▷ お問い合わせ
• ご注文方法:お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
Mordor Intelligence社の本調査資料では、世界の自己免疫治療市場について調査・分析し、イントロダクション、調査手法、エグゼクティブサマリー、市場動向、疾患別(リウマチ性疾患、糖尿病、多発性硬化症、炎症性腸疾患、その他)分析、薬剤分類別(抗炎症剤、血糖降下剤、NSAID、インターフェロン、その他)分析、販売チャネル別(病院薬局、オンライン、その他)分析、地域別(北米、ヨーロッパ、アジア太平洋、中東・アフリカ、南米)分析、競争状況、市場機会・将来の傾向などの項目を掲載しています。
・イントロダクション
・調査手法
・エグゼクティブサマリー
・市場動向
・世界の自己免疫治療市場規模:疾患別(リウマチ性疾患、糖尿病、多発性硬化症、炎症性腸疾患、その他)
・世界の自己免疫治療市場規模:薬剤分類別(抗炎症剤、血糖降下剤、NSAID、インターフェロン、その他)
・世界の自己免疫治療市場規模:販売チャネル別(病院薬局、オンライン、その他)
・世界の自己免疫治療市場規模:地域別(北米、ヨーロッパ、アジア太平洋、中東・アフリカ、南米)
・競争状況(Abbvie、Amgen Inc.、Johnson & Johnson、...)
・市場機会・将来の傾向

The autoimmune treatment market is expected to grow with a CAGR of 4.2%, over the forecast period. The major factor attributing to the growth of the autoimmune treatment market is surge in prevalence of autoimmune diseases. According to NIH (National Institutes of Health) up to 23.5 million Americans have an autoimmune disease and the prevalance is increasing. Scientists have identified 80-100 various autoimmune diseases and assume at least 40 other diseases of having an autoimmune basis. The other factors that play a major role in taking the autoimmune treatment market to the next level are increasing investments in research and development of drugs for autoimmune diseases, technological advancements in diagnosis and awareness of the therapy. Rising government initiatives for regulating these diseases is also helping the growth of the market. However, higher costs of the therapeutics and low medical insurance coverage are constraining the market growth.

Key Market Trends

Rheumatic Disease segment is Expected to Hold Large Market Share

  • The rheumatic disease segment is expected to dominate the market owing to the rising cases of diseases. Rheumatic diseases are described by swelling that affects the connecting structures of the body, mostly the joints, sometimes the tendons, ligaments, bones, and muscles.
  • The therapeutics for rheumatoid disease holds the significant share and expected to remain assertive during the forecast period, due to the rising geriatric population, increasing number of pipeline drugs and the increasing cases of arthritis, fibromyalgia, systemic lupus erythematosus, gout and others, and varied range and availability of progressive therapeutics for the treatment of these diseases.
  • In 2018, according to RheumatoidArthritis.org, around 1.3 million Americans were affected by Rheumatoid arthritis, and the number is increasing every year, which is a driving factor for the autoimmune treatment market.

North America Dominates the Market and Expected to do same in the Forecast Period

North America is expected to dominate the overall autoimmune treatment market, throughout the forecast period. This is due to factors such as the rising incidence and prevalence of autoimmune diseases like arthritis, lupus, multiple sclerosis, in the country. In the North America region, the United States holds the largest market share due to growing personal expenditure on healthcare. The healthcare commerce in the province is developing at a quick stride, resulting in the progress of the North America Autoimmune treatment market. Furthermore, beneficial government initiatives and an increase in the number of research partnerships are some of the drivers expected to increase market growth.

Competitive Landscape

The autoimmune treatment market is moderately competitive and consists of several major players. In terms of market share, few of the major players are currently dominating the market. Some of the companies which are currently dominating the market are AbbVie, Amgen, Johnson & Johnson, Eli Lilly & Co., Pfizer, F. Hoffmann-La Roche AG, Astrazeneca Plc and Bristol-Myers Squibb Co.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support
レポート目次

1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rise in the Prevalence of Autoimmune Diseases
4.2.2 Increasing Investments in Research and development
4.2.3 Advancements in Diagnostic Methods
4.3 Market Restraints
4.3.1 Higher Cost of Therapeutics
4.3.2 Low Medical Insurance Coverage for Autoimmune Diseases
4.4 Porter’s Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION
5.1 By Indication
5.1.1 Rheumatic Disease
5.1.2 Diabetes
5.1.3 Multiple Sclerosis
5.1.4 Inflammatory Bowel Disease
5.1.5 Other Indications
5.2 By Drug Class
5.2.1 Anti-Inflammatory
5.2.2 Anti-Hyperglycemics
5.2.3 NSAIDs
5.2.4 Interferons
5.2.5 Other Drugs
5.3 By Sales Channel
5.3.1 Hospital Pharmacy
5.3.2 Online
5.3.3 Others
5.4 Geography
5.4.1 North America
5.4.1.1 United States
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 United Kingdom
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia-Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Middle-East and Africa
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle-East and Africa
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Abbvie
6.1.2 Amgen Inc.
6.1.3 Johnson & Johnson
6.1.4 Eli Lilly and Company
6.1.5 Pfizer Inc.
6.1.6 F. Hoffmann-La Roche AG
6.1.7 Astrazeneca Plc
6.1.8 Bristol-Myers Squibb Co.
6.1.9 Lupin Limited
6.1.10 GlaxoSmithKline Plc

7 MARKET OPPORTUNITIES AND FUTURE TRENDS